Systemic lupus erythematosus and cardiovascular disease.
Atherosclerosis is an inflammatory disease characterised by presence of activated immune competent cells in middle-sized and large arteries and is the major cause of cardiovascular disease (CVD). The risk of CVD is very high in systemic lupus erythematosus (SLE). SLE-related CVD and atherosclerosis are, therefore, important clinical problems but may in addition also have implications for the role of immune reactions in CVD in general. Others and we have recently demonstrated that risk factors for CVD in SLE are both traditional and non-traditional acting in concert. Traditional risk factors implicated in SLE include, for example, dyslipidemia (especially high triglycerides), hypertension, renal disease, non-traditional as inflammation, antiphospholipid antibodies (aPL) and low-density lipoprotein (LDL) oxidation are also associated with CVD in SLE. Atherothrombosis is likely to be a major underlying mechanism and is not only an increased risk of thrombosis per se. It is possible that factors like proinflammatory reactions or prothrombotic factors, such as aPL, make atherosclerotic lesions in SLE more prone to rupture than in 'normal' atherosclerosis. Whether premature atherosclerosis is a general feature of SLE or only affects a subgroup of patients is presently not clear. Treatment of patients with SLE should include a close monitoring of traditional risk factors and also the above-mentioned non-traditional for CVD.
Frostegård
J
J
Department of Rheumatology, Karolinska University Hospital, Huddinge, Sweden. johan.frostegard@ki.se
D017304:Annexin A5 / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000150:complications* / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000097:blood; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000378:metabolism; D012307:Risk Factors
D017304:Annexin A5; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein